No Data
No Data
Lake Street Maintains OptiNose(OPTN.US) With Buy Rating
Lake Street analyst Thomas Flaten maintains $OptiNose(OPTN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 35.1% and a total average return of -9.5% over the past
Express News | Optinose Announced That Xhance (Fluticasone Propionate) Has Been Added To Express Scripts' National Formularies, Including The National Preferred, Flex, And Basic Formularies
Express News | OptiNose Inc: Expanded Access to Xhance With Addition to National Commercial Formularies
When Will OptiNose, Inc. (NASDAQ:OPTN) Breakeven?
The Market Lifts OptiNose, Inc. (NASDAQ:OPTN) Shares 36% But It Can Do More
OptiNose, Inc. (NASDAQ:OPTN) shareholders are no doubt pleased to see that the share price has bounced 36% in the last month, although it is still struggling to make up recently lost ground. The ba
Express News | OptiNose Inc: OptiNose US & Contract Pharmaceuticals Limited Canada Entered Amendment to Extend Term of Manufacture & Supply Agreement to Dec 31, 2026
loading...
loading...
No Data